par Fernandez-Martinez, Aranzazu;Tanioka, M;Ahn, S G;Zagami, Paola;Pascual, T;Rediti, Mattia 
;Tang, G;Hoadley, Katherine A;Venet, D;Rashid, N U;Spears, P A;Di Cosimo, S;de Azambuja, Evandro ;Choudhury, A;Rastogi, P;Islam, Md Naimul;Cortes, J;Llombart-Cussac, A;Swain, S M;Sotiriou, Christos ;Prat, A;Perou, Charles M;Carey, Lisa A
Référence Annals of oncology
Publication Publié, 2024-12
;Tang, G;Hoadley, Katherine A;Venet, D;Rashid, N U;Spears, P A;Di Cosimo, S;de Azambuja, Evandro ;Choudhury, A;Rastogi, P;Islam, Md Naimul;Cortes, J;Llombart-Cussac, A;Swain, S M;Sotiriou, Christos ;Prat, A;Perou, Charles M;Carey, Lisa ARéférence Annals of oncology
Publication Publié, 2024-12
Article révisé par les pairs
| Résumé : | In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology and prognostic implications across four neoadjuvant studies of trastuzumab with or without lapatinib, and with or without chemotherapy: CALGB 40601, PAMELA, NeoALTTO, and NSABP B-41. |
